Antithrombotic Therapy after Deep Venous Intervention

Abstract

Chronic deep venous disease (CVD) can result in significant morbidity and impact on quality of life due to a spectrum of symptoms, including lower extremity edema, venous claudication, and venous ulcers. CVD can be secondary to both thrombotic and nonthrombotic disease processes, including postthrombotic syndrome from prior deep vein thrombosis (DVT) or iliac vein compression syndrome. Endovascular therapy has become a mainstay therapy for CVD patients, with venous stent placement frequently performed. However, the management of anticoagulation following venous stent placement is not well-studied, with no large trials or consensus guidelines establishing an optimal regimen. The current knowledge gap in antithrombotic therapy is magnified by heterogeneity in practice and data collection, along with incomplete reporting in available studies. Furthermore, most published datasets are antiquated in the setting of rapid evolution in technique and technology available for deep venous intervention. Herein, we summarize the current available literature and offer an approach to anticoagulation and antiplatelet management following deep venous intervention for CVD.

Keywords

interventional radiology - anticoagulation - venous - deep venous thrombosis - postthrombotic syndrome

Publication History

Article published online:
17 November 2022

• References

• 1 Langwieser N, Bernlochner I, Wustrow I. et al. Combination of factor Xa inhibition and antiplatelet therapy after stenting in patients with iliofemoral post-thrombotic venous obstruction. Phlebology 2016; 31 (06) 430-437
• 2 Sebastian T, Spirk D, Engelberger RP. et al. Incidence of stent thrombosis after endovascular treatment of iliofemoral or caval veins in patients with the postthrombotic syndrome. Thromb Haemost 2019; 119 (12) 2064-2073
• 3 Gordon BM, Fishbein MC, Levi DS. Polytetrafluoroethylene-covered stents in the venous and arterial system: angiographic and pathologic findings in a swine model. Cardiovasc Pathol 2008; 17 (04) 206-211
• 4 Faxon DP, Sanborn TA, Haudenschild CC. Mechanism of angioplasty and its relation to restenosis. Am J Cardiol 1987; 60 (03) 5B-9B
• 5 Martufi G, Forneris A, Appoo JJ, Di Martino ES. Is there a role for biomechanical engineering in helping to elucidate the risk profile of the thoracic aorta?. Ann Thorac Surg 2016; 101 (01) 390-398
• 6 AbuRahma AF, Perkins SE, Wulu JT, Ng HK. Iliofemoral deep vein thrombosis: conventional therapy versus lysis and percutaneous transluminal angioplasty and stenting. Ann Surg 2001; 233 (06) 752-760
• 7 Milinis K, Thapar A, Shalhoub J, Davies AH. Antithrombotic therapy following venous stenting: International Delphi Consensus. Eur J Vasc Endovasc Surg 2018; 55 (04) 537-544
• 8 Levine GN, Bates ER, Bittl JA. et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68 (10) 1082-1115
• 9 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149 (02) 315-352
• 10 Wallentin L, Becker RC, Budaj A. et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
• 11 Schömig A. Ticagrelor–is there need for a new player in the antiplatelet-therapy field?. N Engl J Med 2009; 361 (11) 1108-1111
• 12 Iida O, Yokoi H, Soga Y. et al; STOP-IC Investigators. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by Cilostazol study. Circulation 2013; 127 (23) 2307-2315
• 13 Razavi MK, Jaff MR, Miller LE. Safety and effectiveness of stent placement for iliofemoral venous outflow obstruction: systematic review and meta-analysis. Circ Cardiovasc Interv 2015; 8 (10) e002772
• 14 Arendt VA, Mabud TS, Kuo WT. et al. Comparison of anticoagulation regimens following stent placement for nonthrombotic lower extremity venous disease. J Vasc Interv Radiol 2021; 32 (11) 1584-1590
• 15 Tran MA, Lakhanpal P, Lakhanpal S, Satwah VK, Lakhanpal G, Pappas PJ. Type of anti-thrombotic therapy for venous stenting in patients with non-thrombotic iliac vein lesions does not influence the development of in-stent restenosis. Phlebology 2020; 35 (10) 805-813
• 16 Sebastian T, Hakki LO, Spirk D. et al. Rivaroxaban or vitamin-K antagonists following early endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis. Thromb Res 2018; 172: 86-93
• 17 Padrnos L, Garcia D. May-Thurner syndrome and thrombosis: a systematic review of antithrombotic use after endovascular stent placement. Res Pract Thromb Haemost 2018; (03) 70-78
• 18 Endo M, Jahangiri Y, Horikawa M. et al. Antiplatelet therapy is associated with stent patency after iliocaval venous stenting. Cardiovasc Intervent Radiol 2018; 41 (11) 1691-1698
• 19 Sebastian T, Engelberger RP, Spirk D. et al. Cessation of anticoagulation therapy following endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis. Vasa 2019; 48 (04) 331-339
• 20 Murphy E, Gibson K, Sapoval M. et al. Pivotal study evaluating the safety and effectiveness of the ABRE venous self-expanding stent system in patients with symptomatic iliofemoral venous outflow obstruction. Circ Cardiovasc Interv 2022; 15 (02) e010960
• 21 Tincknell LG, Jackson A, Silickas N. et al. Relevance of thrombophilia testing in patients undergoing iliofemoral venous stenting for post-thrombotic occlusion. J Vasc Surg Venous Lymphat Disord 2019; 7 (02) 300-301
• 22 Goldman RE, Arendt VA, Kothary N. et al. Endovascular management of May-Thurner syndrome in adolescents: a single-center experience. J Vasc Interv Radiol 2017; 28 (01) 71-77
• 23 Matsuda A, Yamada N, Ogihara Y. et al. Early and long-term outcomes of venous stent implantation for iliac venous stenosis after catheter-directed thrombolysis for acute deep vein thrombosis. Circ J 2014; 78 (05) 1234-1239
• 24 Nils Kucher RS. Aspirin® plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients with PTS (ARIVA). Accessed September 20, 2022 at https://clinicaltrials.gov/ct2/show/NCT04128956
• 25 McBane II RD, Leadley Jr RJ, Baxi SM, Karnicki K, Wysokinski W. Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct factor Xa inhibitor, compared with antiplatelet agents in pigs. Arterioscler Thromb Vasc Biol 2008; 28 (03) 413-418
• 26 Acuna DE, Allesina S, Kording KP. Future impact: predicting scientific success. Nature 2012; 489 (7415): 201-202
• 27 Li R, Yuan M, Cheng J. et al. Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: a systematic review and meta-analysis. Thromb Res 2020; 196: 340-348
• 28 Zhang X, Huang J, Peng Z, Lu X, Yang X, Ye K. Comparing safety and efficacy of rivaroxaban with warfarin for patients after successful stent placement for chronic iliofemoral occlusion: a retrospective single institution study. Eur J Vasc Endovasc Surg 2021; 61 (03) 484-489
• 29 Downing LJ, Strieter RM, Kadell AM, Wilke CA, Greenfield LJ, Wakefield TW. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis. J Vasc Surg 1998; 28 (05) 848-854
• 30 Eijgenraam P, Cate HT, Cate-Hoek AJ. Venous stenting after deep venous thrombosis and antithrombotic therapy: a systemic review. Rev Vasc Med. 2014; (02) 88-97
• 31 Lin C, Martin KA, Wang M, Stein BL, Desai KR. Long-term antithrombotic therapy after venous stent placement. Phlebology 2020; 35 (06) 402-408